Long term treatment of severe hypercholesterolaemia with guar gum. 1988

J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
National Public Health Institute, Helsinki, Finland.

The long term efficacy of granulated guar gum, 15-30 g per day, was studied in 23 patients with severe hypercholesterolaemia (serum cholesterol concentration between 8.0 and 14.3 mmol/l). Originally, 29 patients participated in the study. Two patients dropped out because of gastrointestinal side effects, two others were not willing to complete the study without any given reason, and two discontinued the study because of hospitalization. A 1-month placebo period preceded the guar gum treatment, and another 1-month placebo period followed after 50 weeks of active treatment. The serum total cholesterol concentration (mean +/- SEM) was reduced from 10.0 +/- 0.4 mmol/l to 8.2 +/- 0.3 mmol/l (P less than 0.001) after 8 weeks and to 9.0 +/- 0.4 mmol/l (P less than 0.001) after 50 weeks on guar gum. During the second placebo period serum cholesterol returned to the pretreatment level. After 34 weeks of active treatment the serum LDL-cholesterol concentration had fallen by 15% and that of apoprotein B by 14% from the baseline. The changes in lipid and lipoprotein levels were independent of the initial values and the type of hypercholesterolaemia. Serum triglycerides, HDL-cholesterol, body weight and blood pressure showed no significant changes during the trial. Of the study subjects, 20 reached the maximum intended dose of 30 g per day guar gum between 8 and 14 weeks and thereafter 11 subjects continued the dose of 30 g/day while 12 subjects reduced the dose to 15-25 g/day.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008351 Mannans Polysaccharides consisting of mannose units. Mannan
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004043 Dietary Fiber The remnants of plant cell walls that are resistant to digestion by the alimentary enzymes of man. It comprises various polysaccharides and lignins. Fiber, Dietary,Roughage,Wheat Bran,Bran, Wheat,Brans, Wheat,Dietary Fibers,Fibers, Dietary,Roughages,Wheat Brans
D005260 Female Females

Related Publications

J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
October 1982, Atherosclerosis,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
April 1986, Atherosclerosis,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
December 1985, Diabetes research and clinical practice,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
October 1993, The American journal of clinical nutrition,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
January 1995, BMJ (Clinical research ed.),
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
April 1995, Diabetes care,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
May 1985, The American journal of clinical nutrition,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
August 2020, RSC advances,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
January 1990, Duodecim; laaketieteellinen aikakauskirja,
J Tuomilehto, and M Silvasti, and A Aro, and A Koistinen, and P Karttunen, and C G Gref, and C Ehnholm, and M Uusitupa
January 1985, Progress in clinical and biological research,
Copied contents to your clipboard!